# A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

> **NCT02129205** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 40 (actual)

## Conditions studied

- Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** PF-06650808
- **DRUG:** PF-06650808

## Key facts

- **NCT ID:** NCT02129205
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** The study was terminated due to a change in sponsor prioritization.
- **Last updated:** 2019-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129205, "A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02129205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*